Brain

PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private PlacementPreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement

PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),…

5 days ago
Neurostimulation Devices Market to Reach USD 17.2 Billion by 2031 – Driven by Demand for Pain and Parkinson’s Therapies | Valuates ReportsNeurostimulation Devices Market to Reach USD 17.2 Billion by 2031 – Driven by Demand for Pain and Parkinson’s Therapies | Valuates Reports

Neurostimulation Devices Market to Reach USD 17.2 Billion by 2031 – Driven by Demand for Pain and Parkinson’s Therapies | Valuates Reports

BANGALORE, India, May 22, 2025 /PRNewswire/ -- Neurostimulation Devices Market is Segmented by Type (Spinal Cord Stimulation (SCS), Gastric Electric…

6 days ago
Corundum Neuroscience and Corundum Systems Biology to Host Panel Sessions at First Ever SXSW LondonCorundum Neuroscience and Corundum Systems Biology to Host Panel Sessions at First Ever SXSW London

Corundum Neuroscience and Corundum Systems Biology to Host Panel Sessions at First Ever SXSW London

Discussions to Focus on the Role of Sleep Innovation for Brain Health and the Influence of the Microbiome on Human…

6 days ago
Neurophet Participates ASNR 2025: Showcasing Clinical Utility of ‘Neurophet AQUA AD’Neurophet Participates ASNR 2025: Showcasing Clinical Utility of ‘Neurophet AQUA AD’

Neurophet Participates ASNR 2025: Showcasing Clinical Utility of ‘Neurophet AQUA AD’

Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA ADCompany accelerates…

7 days ago
Neurogen Biomarking Announces Partnership with AransciaNeurogen Biomarking Announces Partnership with Aranscia

Neurogen Biomarking Announces Partnership with Aranscia

Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and…

7 days ago
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increaseMedtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May…

7 days ago
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Study is expected to deliver final device data and documentation needed for planned FDA IND submissionSARASOTA, FL, May 21, 2025…

7 days ago
ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s DiseaseABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease

ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease

Agency supports primary and novel secondary and exploratory endpoints proposed for Phase 3 Trial(s) Opportunity to utilize time-to-delay of levodopa/carbidopa…

7 days ago
Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy StudyRoute 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study

Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study

Data from 250-patient, 31-center, randomized controlled trial presented at European Stroke Organisation Conference Three highest enrolling sites reported 96% delivery…

7 days ago
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s diseaseGalimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory.Improves Memory…

7 days ago